<PAGE>
Conformed
Copy
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 1998
------------
CYTOGEN CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-02015 22-2322400
- --------------- ----------- -------------
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification No.)
Incorporation or
Organization)
600 College Road East, CN 5308, Princeton, New Jersey 08540-5308
-----------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 987-8200
<PAGE>
Item 5. Other Events.
-------------
On May 22, 1998, CYTOGEN Corporation issued the attached press release.
Item 7. Exhibits.
---------
99.1 Press release issued by CYTOGEN Corporation on May 22, 1998
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
CYTOGEN CORPORATION
By /s/ John E. Bagalay, Jr.
---------------------------
Name: John E. Bagalay, Jr.
Title: President and Chief Executive Officer
Date: May 22, 1998
3
<PAGE>
EXHIBIT INDEX
Number Description Page
99.1 Press Release issued by CYTOGEN Corporation on
May 22, 1998 5
4
<PAGE>
Contacts: Donald Crane Angela M. Bitting
CYTOGEN Corporation Russell-Welsh, Inc.
(609)520-3062 (650)312-0700, ext. 15
CYTOGEN SUES DUPONT MERCK FOR BREACH OF
QUADRAMET LICENSE AGREEMENT
PRINCETON, NJ - May 22, 1998 - CYTOGEN Corporation (Nasdaq:CYTO)
announced today that it filed suit in the Superior Court of the
State of New Jersey against The DuPont Merck Pharmaceutical Company
asserting that DuPont Merck failed to fulfill its obligations under
an agreement to market Quadramet. CYTOGEN's product for the relief
of bone pain caused from cancer which has spread to the bone.
DuPont Merck had notified CYTOGEN that it would cease marketing
Quadramet on Monday, May 25, 1998 on the grounds that CYTOGEN
allegedly breached the license agreement between CYTOGEN and DuPont
Merck dated December 20, 1994. CYTOGEN believes DuPont Merck's
allegations are wholly unsupportable, and has filed the lawsuit in
an effort to enforce DuPont Merck's obligation to market Quadramet.
John Bagalay, President and Chief Executive Officer of CYTOGEN
said, "We are extremely concerned about any disruption of patient
therapy which may be caused by these marketing actions and are
aggressively pursuing options to assure the continued delivery of
Quadramet therapy to patients with bone pain."
Under the terms of the license agreement, DuPont Merck has the
responsibility to manufacture and market Quadramet in the United
States. CYTOGEN is responsible for certain regulatory approvals
and clinical development of Quadramet for other indications.
Quadramet was cleared for marketing by the U.S. Food and Drug
Administration in March of 1997 for the treatment of bone pain
associated with cancers that have spread to the bone. In May 1997,
DuPont Merck began marketing Quadramet.
CYTOGEN is a biopharmaceutical company engaged in the development,
manufacture and commercialization of products for the targeted
delivery of diagnostics and therapeutic substances directly to
disease sites. CYTOGEN has demonstrated its ability to develop new
technology from early discovery through clinical development,
regulatory approval and commercial scale biologic manufacturing.
Information in this press release, which is not historical, is
forward looking and involves risks and uncertainties. Actual
results may differ materially, for reasons discussed in the
Company's filings with the Securities and Exchange Commission,
including risks related to unanticipated expenses which may
reduce the Company's ability to achieve maximum efficiencies
from the change in business strategies, the ability to find a
suitable partner for further development of the technology,
and commercial acceptance of the Company's products.
# # #
